carboxyphosphamide profile

Carboxyphosphamide is a nitrogen mustard derivative that has been studied as an anticancer agent. Its synthesis involves reacting cyclophosphamide with carbon dioxide. Carboxyphosphamide exhibits antitumor activity in preclinical models, demonstrating cytotoxic effects against various cancer cell lines. It is studied due to its potential to overcome limitations associated with traditional nitrogen mustard chemotherapy, such as drug resistance and toxicity. Research efforts focus on optimizing its pharmacological properties and investigating its clinical efficacy in treating specific types of cancer.'
```

carboxyphosphamide: metabolite of cyclophosphamide; RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	31515
CHEMBL ID	3544547
CHEBI ID	3410
MeSH ID	M0040044

Synonym
asta 5754
brn 2053657
hydracrylic acid, n,n-bis(2-chloroethyl)phosphorodiamidate
propanoic acid, 3-((amino(bis(2-chloroethyl)amino)phosphinyl)oxy)-
ccris 5126
2-carboxyethyl-n,n-bis(2-chloroethyl)phosphorodiamidate
C07646
carboxycyclophosphamide
22788-18-7
carboxyphosphamide
propanoic acid, 3-[[amino[bis(2-chloroethyl)amino]phosphinyl]oxy]-
nsc-145124
nsc145124
nsc 145124
o-(2-carboxyethyl) n,n-bis(2-chloroethyl)phosphorodiamidate
hydracrylic acid,n-bis(2-chloroethyl)phosphorodiamidate
FT-0664360
3-[amino-[bis(2-chloroethyl)amino]phosphoryl]oxypropanoic acid
dp4677ax41 ,
unii-dp4677ax41
3-[[amino[bis(2-chloroethyl)amino]phosphinyl]oxy]propanoic acid
CHEBI:3410 ,
cepm
propanoic acid, 3-((amino(bis(2-chloroethyl)amino)phosphinyl)oxy)- (9ci)
asta-5754
CHEMBL3544547
AKOS027322743
J-014854
2-carboxyethyl n,n-bis(2-chloroethyl)phosphorodiamidate
Q15716203
3-({amino[bis(2-chloroethyl)amino]phosphoryl}oxy)propanoic acid
DTXSID801030866
3-((amino(bis(2-chloroethyl)amino)phosphoryl)oxy)propanoic acid

Excerpt	Reference	Relevance
" A population pharmacokinetic model for cyclophosphamide was developed using non-linear mixed effects modelling and metabolite AUC values were compared between days and courses."	( Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy. Boddy, AV; Chinnaswamy, G; Cole, M; Errington, J; Foot, A; Veal, GJ, 2011)	0.37

Class	Description
nitrogen mustard	Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Metabolism	1496	1108
Biological oxidations	150	276
Phase I - Functionalization of compounds	69	175
Cyclophosphamide Action Pathway	9	22
Cyclophosphamide Metabolism Pathway	9	22

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (30.77)	18.7374
1990's	6 (46.15)	18.2507
2000's	1 (7.69)	29.6817
2010's	2 (15.38)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
chloral hydrate [no description available]	1.98	1	aldehyde hydrate; ethanediol; organochlorine compound	general anaesthetic; mouse metabolite; sedative; xenobiotic
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.08	1	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
ifosfamide [no description available]	1.98	1	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
cyanides Cyanides: Inorganic salts of HYDROGEN CYANIDE containing the -CN radical. The concept also includes isocyanides. It is distinguished from NITRILES, which denotes organic compounds containing the -CN radical.. cyanides : Salts and C-organyl derivatives of hydrogen cyanide, HC#N.. isocyanide : The isomer HN(+)#C(-) of hydrocyanic acid, HC#N, and its hydrocarbyl derivatives RNC (RN(+)#C(-)).. cyanide : A pseudohalide anion that is the conjugate base of hydrogen cyanide.	1.96	1	pseudohalide anion	EC 1.9.3.1 (cytochrome c oxidase) inhibitor
acrolein [no description available]	1.98	1	enal	herbicide; human xenobiotic metabolite; toxin
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	1.98	1	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
nornitrogen mustard nornitrogen mustard: structure; RN given refers to parent cpd	1.98	1	nitrogen mustard
cyanamide Cyanamide: A cyanide compound which has been used as a fertilizer, defoliant and in many manufacturing processes. It often occurs as the calcium salt, sometimes also referred to as cyanamide. The citrated calcium salt is used in the treatment of alcoholism.. cyanamide : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by an amino group.	6.96	1	nitrile; one-carbon compound	EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor
4-ketocyclophosphamide 4-ketocyclophosphamide: metabolite of cyclophosphamide; RN given refers to cpd without isomeric designation; structure	3.08	5	nitrogen mustard
oxazolidin-2-one Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.	1.98	1	carbamate ester; oxazolidinone	metabolite
4-hydroxycyclophosphamide 4-hydroxycyclophosphamide: primary activation metabolite of cyclophosphamide; RN given refers to cpd without isomeric designation. 4-hydroxycyclophosphamide : A phosphorodiamide that consists of 2-amino-1,3,2-oxazaphosphinan-4-ol 2-oxide having two 2-chloroethyl groups attached to the exocyclic nitrogen.	6.96	1	nitrogen mustard; organochlorine compound; phosphorodiamide	alkylating agent; metabolite
aldophosphamide aldophosphamide: metabolite of cyclophosphamide	7.66	3	nitrogen mustard
dechloroethylcyclophosphamide dechloroethylcyclophosphamide: structure given in first source; RN given refers to parent cpd	2.69	3	phosphorodiamide
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	1.98	1	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
afimoxifene afimoxifene : A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen.	2.08	1	phenols; tertiary amino compound	antineoplastic agent; estrogen receptor antagonist; metabolite
retinaldehyde Retinaldehyde: A diterpene derived from the carotenoid VITAMIN A which functions as the active component of the visual cycle. It is the prosthetic group of RHODOPSIN (i.e., covalently bonded to ROD OPSIN as 11-cis-retinal). When stimulated by visible light, rhodopsin transforms this cis-isomer of retinal to the trans-isomer (11-trans-retinal). This transformation straightens-out the bend of the retinal molecule and causes a change in the shape of rhodopsin triggering the visual process. A series of energy-requiring enzyme-catalyzed reactions convert the 11-trans-retinal back to the cis-isomer.. all-trans-retinal : A retinal in which all four exocyclic double bonds have E- (trans-) geometry.	1.98	1	retinal; vitamin A	gap junctional intercellular communication inhibitor; human metabolite; mouse metabolite
tamoxifen [no description available]	2.08	1	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
mesna Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.	2.39	2	organosulfonic acid

Condition	Relationship Strength	Studies
Sarcoma, Epithelioid [description not available]	2.06	1
Mesenchymoma A mixed mesenchymal tumor composed of two or more mesodermal cellular elements not commonly associated, not counting fibrous tissue as one of the elements. Mesenchymomas are widely distributed in the body and about 75% are malignant. (Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1866)	2.06	1
Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)	2.06	1
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	2.06	1
Recrudescence [description not available]	2.02	1
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	2.02	1
B-Cell Lymphoma [description not available]	2.02	1
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	2.02	1
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	2.02	1
MS (Multiple Sclerosis) [description not available]	1.96	1
Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)	1.96	1
Benign Neoplasms [description not available]	2.89	4
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.89	4

carboxyphosphamide

Description

Cross-References

Synonyms (33)

Research Excerpts

Pharmacokinetics

Drug Classes (1)

Pathways (5)

Research

Studies (13)

Market Indicators

Research Demand Index: 17.16

Study Types